Thermo Fisher Scientific has inaugurated its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco, marking a significant advancement in the field of drug discovery. This cutting-edge facility aims to provide pharmaceutical and biotechnology companies with unparalleled access to state-of-the-art cryo-EM technologies. These technologies are designed to enhance structural insights and expedite the development of innovative therapies.
Accelerating Drug Development
The advent of cryo-EM technology has revolutionized the landscape of drug development by broadening the scope of therapeutic targets. According to Thermo Fisher, the ability to utilize structure-based methods significantly shortens the timeline for getting drugs into clinical settings. Structure-guided drugs reportedly experience more than double the clinical success rate, with a dramatic reduction in both preclinical time and costs compared to traditional industry benchmarks.
Collaborative Research Environment
Glyn Davies, president of materials and structural analysis at Thermo Fisher, emphasized the center’s role in fostering collaboration. He stated that the Cryo-EM Drug Discovery Center creates an environment where scientists can leverage cryo-EM to deepen their understanding of diseases at the molecular level. This collaborative approach aims to accelerate the development of new therapeutics, ultimately benefiting patients and the healthcare system.
Building on Past Success
The establishment of the CDDC in South San Francisco builds on the success of the UK Pharmaceutical Cryo-EM Consortium, which was launched in Cambridge in 2016. This consortium has facilitated a longstanding partnership between Thermo Fisher Scientific and several leading pharmaceutical companies. The U.S. center will adopt a similar collaborative model, inviting founding customer members to participate in advancing drug discovery in North America.
Enhancing Structural Biology
Cryo-EM technology offers remarkable advantages in structural biology, allowing scientists to visualize biomolecules in their native states. This capability is crucial for understanding the intricate details of disease mechanisms and the interactions between drugs and their targets. By harnessing cryo-EM, researchers can design more effective therapeutics tailored to specific diseases, particularly in oncology and immuno-oncology.
The Future of Drug Discovery
The implications of the CDDC extend beyond immediate research benefits. By streamlining the drug discovery process, Thermo Fisher’s investment in cryo-EM technology can potentially lead to faster access to life-saving therapies for patients. The center represents a commitment to innovation and collaboration in a rapidly evolving field.
Key Takeaways
- The Cryo-EM Drug Discovery Center opened in South San Francisco by Thermo Fisher Scientific aims to enhance drug development processes.
- Cryo-EM technology facilitates faster drug development with improved clinical success rates.
- A collaborative environment fosters partnerships between scientists and pharmaceutical companies for innovative therapeutic solutions.
In conclusion, Thermo Fisher Scientific’s Cryo-EM Drug Discovery Center is a promising development in the biotech landscape. By merging advanced technology with collaborative research, the center is poised to accelerate the journey from discovery to therapy, potentially transforming patient care in the years to come.
Read more → www.genengnews.com